IN2015DN03219A - - Google Patents

Info

Publication number
IN2015DN03219A
IN2015DN03219A IN3219DEN2015A IN2015DN03219A IN 2015DN03219 A IN2015DN03219 A IN 2015DN03219A IN 3219DEN2015 A IN3219DEN2015 A IN 3219DEN2015A IN 2015DN03219 A IN2015DN03219 A IN 2015DN03219A
Authority
IN
India
Prior art keywords
pridopidine
laquinimod
treating
neurodegenerative disorder
provides
Prior art date
Application number
Other languages
English (en)
Inventor
Michael Hayden
Dan Bar-Zohar
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IN2015DN03219A publication Critical patent/IN2015DN03219A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Mechanical Engineering (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN3219DEN2015 2012-09-27 2013-09-27 IN2015DN03219A (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261706695P 2012-09-27 2012-09-27
US201361879004P 2013-09-17 2013-09-17
PCT/US2013/062482 WO2014052933A1 (en) 2012-09-27 2013-09-27 Laquinimod and pridopidine for treating neurodegenerative disorders

Publications (1)

Publication Number Publication Date
IN2015DN03219A true IN2015DN03219A (he) 2015-10-02

Family

ID=50339469

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3219DEN2015 IN2015DN03219A (he) 2012-09-27 2013-09-27

Country Status (13)

Country Link
US (7) US20140088140A1 (he)
EP (1) EP2900330A4 (he)
CN (1) CN104902958A (he)
AU (1) AU2013323131A1 (he)
BR (1) BR112015006623A2 (he)
CA (1) CA2884781A1 (he)
EA (1) EA201590655A8 (he)
HK (2) HK1211525A1 (he)
IL (1) IL237742A0 (he)
IN (1) IN2015DN03219A (he)
MX (1) MX2015003608A (he)
WO (1) WO2014052933A1 (he)
ZA (1) ZA201502600B (he)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
EP2146961B1 (en) * 2007-04-12 2014-01-29 IVAX International GmbH N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
CA2810092A1 (en) 2010-09-03 2012-03-08 IVAX International GmbH Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US9006445B2 (en) 2011-09-07 2015-04-14 IVAX International GmbH Polymorphic form of pridopidine hydrochloride
US9012476B2 (en) 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
UA122999C2 (uk) 2013-06-21 2021-02-03 Прайлінія Н'Юротерапьютікс Лтд. Застосування придопідину для лікування хвороби гантінгтона
KR20160110395A (ko) * 2013-12-20 2016-09-21 테바 파마슈티컬 인더스트리즈 리미티드 헌팅턴병 진행을 지연시키기 위한 라퀴니모드의 용도
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
EP3193870A4 (en) * 2014-09-16 2018-04-25 Teva Pharmaceutical Industries Ltd. Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod
CA2970799A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
DK3261721T3 (da) * 2015-02-25 2022-11-28 Prilenia Neurotherapeutics Ltd Anvendelse af pridopidin til forbedring af hukommelse
US20170020854A1 (en) * 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017048457A1 (en) * 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
MX2019002265A (es) 2016-08-24 2019-10-30 Prilenia Therapeutics Dev Ltd Uso de pridopidina para el tratamiento de la disminucion funcional.
US11253594B2 (en) 2017-07-07 2022-02-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Drug combinations for protecting against neuronal cell death
CN116370473A (zh) 2017-08-14 2023-07-04 普瑞尼亚神经治疗有限公司 用普利多匹定治疗肌萎缩性脊髓侧索硬化症的方法
EA202193190A1 (ru) * 2019-06-12 2022-03-24 Прилиния Ньюротерапьютикс Лтд. Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101765428A (zh) * 2007-06-18 2010-06-30 A·卡尔森研究股份有限公司 多巴胺稳定剂的用途
WO2010057006A1 (en) * 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
DK2467372T3 (en) * 2009-08-10 2016-08-22 Teva Pharma TREATMENT OF BDNF-RELATED DISEASES USING LAQUINIMOD
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
EA201390827A1 (ru) * 2010-12-07 2013-12-30 Тева Фармасьютикал Индастриз Лтд. Применение лаквинимода для уменьшения утомляемости, улучшения функционального состояния и улучшения качества жизни пациентов с рассеянным склерозом

Also Published As

Publication number Publication date
IL237742A0 (he) 2015-05-31
AU2013323131A1 (en) 2015-05-07
ZA201502600B (en) 2016-06-29
HK1214553A1 (zh) 2016-07-29
MX2015003608A (es) 2015-06-05
US20180250285A1 (en) 2018-09-06
CA2884781A1 (en) 2014-04-03
US20150209346A1 (en) 2015-07-30
EA201590655A8 (ru) 2016-07-29
WO2014052933A1 (en) 2014-04-03
US20180133209A1 (en) 2018-05-17
EA201590655A1 (ru) 2015-12-30
US20170319569A1 (en) 2017-11-09
EP2900330A4 (en) 2016-05-25
CN104902958A (zh) 2015-09-09
EP2900330A1 (en) 2015-08-05
BR112015006623A2 (pt) 2017-07-04
HK1211525A1 (en) 2016-05-27
US20190117639A1 (en) 2019-04-25
US20140088140A1 (en) 2014-03-27
US20180369228A1 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
IN2015DN03219A (he)
WO2014052935A3 (en) Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
MX365835B (es) Uso de akkermansia para tratar trastornos metabolicos.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2018002990A (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos.
PH12014501560A1 (en) Carbamate compounds and of making and using same
MY166014A (en) Combination therapy methods for treating proliferative diseases
SG10201810888XA (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
MX2021005317A (es) Composiciones y métodos para absorción transmucosa.
PH12016500296A1 (en) Sodium channel modulators for the treatment of pain and diabetes
BR112012022552A2 (pt) uso de fenoterol e de anélogos de fenoterol no tratamento de gliobastomas e astrocitomas
MX2015012315A (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
MX2015000485A (es) Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
MX370451B (es) Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi metil)-naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular.
MX2016001177A (es) Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina.
MX2014013491A (es) Metodos para mantener, tratar o mejorar la funcion cognitiva.
IN2013MU01155A (he)
IN2013MU01252A (he)
IN2013MU01154A (he)
IN2013MU01247A (he)
IN2013MU01250A (he)